دورية أكاديمية
Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: A versatile and practical infection model for antiviral research and beyond.
| العنوان: | Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: A versatile and practical infection model for antiviral research and beyond. |
|---|---|
| المؤلفون: | Salgado-Benvindo C; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Tas A; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Zevenhoven-Dobbe JC; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., van der Meer Y; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Sidorov IA; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Leijs AA; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Wanningen P; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., Gelderloos AT; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 3720 BA, Bilthoven, the Netherlands., van Kasteren PB; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 3720 BA, Bilthoven, the Netherlands., Snijder EJ; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands., van Hemert MJ; Molecular Virology Laboratory, Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA, Leiden, the Netherlands. Electronic address: m.j.van_hemert@lumc.nl. |
| المصدر: | Antiviral research [Antiviral Res] 2024 Jul; Vol. 227, pp. 105903. Date of Electronic Publication: 2024 May 07. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9096 (Electronic) Linking ISSN: 01663542 NLM ISO Abbreviation: Antiviral Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam : Elsevier Original Publication: [Amsterdam ; New York : Elsevier/North-Holland Biomedical Press, c1981- |
| مواضيع طبية MeSH: | SARS-CoV-2*/physiology , SARS-CoV-2*/drug effects , Virus Replication*/drug effects , Angiotensin-Converting Enzyme 2*/metabolism , Antiviral Agents*/pharmacology , COVID-19*/virology, Humans ; Animals ; Chlorocebus aethiops ; Vero Cells ; Cell Line |
| مستخلص: | A range of cell culture infection models have been used to study SARS-CoV-2 and perform antiviral drug research. Commonly used African green monkey Vero, human lung-derived Calu-3 and ACE2+TMPRSS2-expressing A549 cells, each have their limitations. Here, we describe human ACE2-expressing H1299 lung cells as a more efficient and robust model for SARS-CoV-2 research. These cells are as easy to handle as Vero cells, support SARS-CoV-2 replication to high titers, display a functional innate immune response and are suitable for plaque assays, microscopy, the production of (genetically stable) virus stocks and antiviral assays. H1299/ACE2-based (CPE reduction) assays can be performed without adding a P-gP drug efflux pump inhibitor, which is often required in Vero-based assays. Moreover, H1299/ACE2 cells allowed us to perform CPE reduction assays with omicron variants that did not work in Vero-based assays. In summary, H1299/ACE2 cells are a versatile infection model to study SARS-CoV-2 replication in the context of antiviral drug development and virus-host interaction studies. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Infection model; Lung cells; SARS-CoV-2 |
| المشرفين على المادة: | EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) 0 (Antiviral Agents) EC 3.4.17.23 (ACE2 protein, human) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20240509 Date Completed: 20240617 Latest Revision: 20240923 |
| رمز التحديث: | 20240923 |
| DOI: | 10.1016/j.antiviral.2024.105903 |
| PMID: | 38723907 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1872-9096 |
|---|---|
| DOI: | 10.1016/j.antiviral.2024.105903 |